TRVN Trevena
- 0.4095
- +0.0257+6.70%
Trevena News
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersChromocell Therapeutics (AMEX:CHRO) stock increased by 21.6% to $1.49 during Friday's pre-market session. The company's market cap stands at $8.7 million. Kineta (NASDAQ:KA) stock moved upwards
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) shares increased by 43.8% to $4.66 during Thursday's pre-market session. The market value of their outstanding shares is at $3.5 million. SINTX Techs (NASDAQ:SINT)
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersTrevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday's after-market session. The company's market cap stands at $9.2 million. Mustang Bio (NASDAQ:MBIO) stock increased by 1
Trevena Is Maintained at Buy by HC Wainwright & Co.
Trevena Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Trevena, Maintains $9 Price Target
HC Wainwright & Co. analyst Douglas Tsao maintains Trevena (NASDAQ:TRVN) with a Buy and maintains $9 price target.
Buy Rating Affirmed on Trevena as Focus Shifts to Promising Drug Candidate TRV045
Buy Rating Affirmed for Trevena Amid Strategic Focus on Promising TRV045 Development
Recap: Trevena Q4 Earnings
Trevena (NASDAQ:TRVN) reported its Q4 earnings results on Monday, April 1, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsTrevena missed estimated earnings by -179.
Trevena Q4 EPS $(1.06) Misses $(0.38) Estimate, Cash Balance of $33M
Trevena (NASDAQ:TRVN) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.38) by 178.95 percent. This is a 45.21 percent decrease over losses of $(0.73) p
Press Release: Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical
Trevena 4Q Loss $16.5M >TRVN
Trevena 4Q Loss $16.5M >TRVN
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
Trevena Inc Unveils Updated Corporate Strategy Presentation
12 Health Care Stocks Moving In Friday's After-Market Session
GainersSalarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The market value of their outstanding shares is at $3.2 million. Masimo (NASDAQ:MASI) sha
HC Wainwright & Co. Reiterates Buy on Trevena, Maintains $9 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Trevena (NASDAQ:TRVN) with a Buy and maintains $9 price target.
Trevena Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/11/2024 1536.36% HC Wainwright & Co. → $9 Reiterates Buy → Buy 05/17/2023 263.64% JMP Securities → $2 R
Analysts Offer Insights on Healthcare Companies: Trevena (TRVN), MoonLake Immunotherapeutics (MLTX) and Senseonics Holdings (SENS)
Trevena Faces Nasdaq Delisting Over Share Price
Trevena Granted US Patent 11,912,693 Titled 'Compounds For Modulating S1P1 Activity And Methods Of Using The Same'
Trevena Granted US Patent 11,912,693 Titled 'Compounds For Modulating S1P1 Activity And Methods Of Using The Same'
Trevena Has Been Granted U.S. Patent 11,912,713 Titled "7-membered Aza-Heterocyclic Containing Delta-Opioid Receptor Modulating Compounds, Methods Of Using And Making (For Treating Pain, Migraines, Depression, Parkinsons Disease, And Other Disorders)
Trevena Has Been Granted U.S. Patent 11,912,713 Titled "7-membered Aza-Heterocyclic Containing Delta-Opioid Receptor Modulating Compounds, Methods Of Using And Making (For Treating Pain, Migraines, De
Analysis
Price Target
No Data
